JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v8i2.5537ArticleResearch on the Correlation Between rs2110385 Polymorphisms of the Visfatin Gene and Nonproliferative Diabetic Retinopathyhttps://artdesignp.com/journal/JCNR/8/2/10.26689/jcnr.v8i2.5537ZhangMin,LiRong,MaWei-guo,YinXiao-hong,LiYa2024822024-02-26Objective: To investigate the association between rs2110385 polymorphisms of the visfatin gene and the risk of type 2 diabetic retinopathy (DR). Methods: 172 Han subjects were selected from Xi’an Shaanxi Province；140 patients with type 2 diabetes mellitus (T2DM) and 32 normal controls (NC) were selected from our hospital. Patients with diabetes were divided into a non-DR group (T2DM) (n = 69) and a nonproliferative diabetic retinopathy Group (DR) (n =71) after dilated fundus photography and fundus fluorescein angiography. rs2110385/Alu Ⅰ genotypes were detected by standardized polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), and the differences in the detection rates of different genotypes in the above populations were compared. Results: 1) The visfatin level in the DR Group was significantly higher than that in the NC and T2DM groups (P < 0.05). 2) The frequency of GG genotype and G allele of rs2110385 in the DR Group were higher than those in the T2DM and NC groups (80.3, 69.6, 50.0, 86.6, 79, 65.6, P < 0.05). 3) There were significant differences in allele frequency and genotype frequency distribution of rs2110385 between the DR Group and the NC group (P < 0.01). Conclusion: Visfatin increased in the nonproliferative diabetic retinopathy group and could be a potential indicator for the clinical prediction of DR. The G allele of the rs2110385 polymorphic site may be related to the risk of DR.

Franco-Trepat E, Guillán-Fresco M, Alonso-Pérez A, et al., 2019, Visfatin Connection: Present and Future in

Osteoarthritis and Osteoporosis. J Clin Med, 8(8): 1178.

Martínez Larrad MT, Corbatón Anchuelo A, Fernández Pérez C, et al., 2016, Obesity and Cardiovascular Risk: Variations in Visfatin Gene Can Modify the Obesity Associated Cardiovascular Risk. Results from the Segovia Population Based-Study. PLoS One, 11(5): e0153976.

Lu J, Liu X, and Li H, 2022, The Effect of Visfatin Genotype on Insulin Pump Therapy on Quality of Life in Patients with Type I Diabetes. Cellular and Molecular Biology, 67 (4): 195–202.

Solomon SD, Chew E, Duh EJ, et al., 2017, Diabetic Retinopathy: A Position Statement by the American Diabetes Association.Diabetes Care, 40(3): 412–418.

Xiang H, Zhang H, 2010, ADA: Medical Diagnosis and Treatment Standards for Diabetes. Chinese Journal of Diabetes, 18(3): 164–171.

Fundus Disease Group of the Chinese Medical Association of Ophthalmology, 2014, Guidelines for Clinical Diagnosis and Treatment of Diabetic Retinopathy In China. Chinese Journal of Ophthalmology, 50(11): 851–865.

Heo YJ, Choi SE, Jeon JY, et al., 2019, Visfatin Induces Inflammation and Insulin Resistance via the NF-?B and

STAT3 Signaling Pathways in Hepatocytes. J Diabetes Res, 2019: e4021623.

Stejskal D, Sigutova R, Svestak M, et al., 2020, Measurement of Novel Adipokine Visfatin in Young Patients with

Acute Myocardial Infarction. Clinical Testing of a New ELISA. Biomed Pap Med Fac Univ Palacky Olomouc Czech

Repub, 164(2): 138–140.

Motawi TM, Shaker OG, El-Sawalhi MM, et al., 2014, Visfatin -948G/T and Resistin -420C/G Polymorphisms in Egyptian Type 2 Diabetic Patients with and Without Cardiovascular Diseases. Genome, 57(5): 259–266.

Chen D, Wang Y, Liu M, et al., 2021, Visfatin Promotes the Angiogenesis of RF/6A Cells through the Upregulation of VEGF/VEGFR-2 under High-Glucose Conditions. Exp Ther Med, 21(4): 389.

Yu L, Shi L, Dai L, et al., 2010, Correlation between Visfatin Gene Promoter Polymorphism and Lipid Metabolism Disorder in Chinese Type 2 Diabetes. Chinese Journal of Gerontology, 30(22): 3250–3252.

Zhang W, 2009, Correlation between Visfatin Gene Polymorphisms and Type 2 Diabetes in the Han Population in

Gansu, dissertation, Lanzhou University.

Wang Y, Yan L, Wu J, et al., 2011, The Relationship between Visfatin Gene Polymorphism and Type 2 Diabetes. Journal of Xi’an Jiaotong University (Medical Edition), 32(4): 453–457.

Jin LW, Zheng SB, Zhou ZH, et al., 2016, Correlation between Polymorphisms in the Visfatin Gene and its Expression in the Serum and Coronary Artery Calcification. Genet Mol Res, 15(2): e15028217.

Paschou P, Kukuvitis A, Yavropoulou MP, et al., 2010, Genetic Variation in the Visfatin (PBEF1/NAMPT) Gene and Type 2 Diabetes in the Greek Population. Cytokine, 51(1): 25– 27.

Liu F, Shan C, Luo J, et al., 2021, Study on the Association between Visfatin Gene Rs61330082 and rs4730153 Polymorphisms and Blood Lipid Levels and Acute Coronary Syndrome. Journal of Xinjiang Medical University, 44(1):18–23 + 27.

Marjani S, Nezhadali M, Hekmat A, et al., 2022, Investigating Visfatin Gene Polymorphism rs4730153 with Insulin

Resistance and Non-Alcoholic Fatty Liver Diseases in Iranian Population. Iran J Public Health, 51(5): 1143–1151.

Zhang L, Yang X, Chen S, 2011, Effects of Rosiglitazone on Serum Visfatin and VCAM-1 Level and Visfatin Mrna

Expression in Visceral Adipose Tissue of IR Rats. Hebei Medicine, 33(2): 184–185.